(Q46626407)

23 December 2017

title

Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema (English)

1 reference

23 December 2017

1 reference

A Ozkiriş

1

1 reference

23 December 2017

publication date

25 April 2008

1 reference

23 December 2017

published in

Eye

1 reference

23 December 2017

volume

23

1 reference

23 December 2017

issue

3

1 reference

23 December 2017

page(s)

616-620

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1038/eye.2008.40

exact match

0 references

cites work

Diabetic macular edema: review and update

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

The pathogenesis of edema in diabetic maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Pattern electroretinogram for monitoring the efficacy of intravitreal triamcinolone injection in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Intravitreal triamcinolone for refractory diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

A controlled study of vitrectomy for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

The potential role of PKC beta in diabetic retinopathy and macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Reproducibility of volumetric measurements of normal maculae with the Heidelberg retina tomograph

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Complications of intravitreal injection of triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Retinal complications of intravitreal injections of triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

7 January 2021

Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

7 January 2021

Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

7 January 2021

Vascular endothelial growth factor is a critical stimulus for diabetic macular edema

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

7 January 2021

Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

7 January 2021

Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

7 January 2021

Safety of intravitreal injection of bevacizumab in rabbit eyes

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

7 January 2021

Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

7 January 2021

Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

7 January 2021

Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin)

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

7 January 2021

Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.40

7 January 2021

Identifiers

DOI

10.1038/EYE.2008.40

1 reference

23 December 2017

PubMed ID

18437176

1 reference

23 December 2017